Evidence map›Paper›PMID 40673930›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2025

CD8 + T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA.

Zihan Yuan, Wei He, Wenjia Luo, Chunxia Huang, Miao Li, Jie You, Jiaqiang Wu, Kangping Yang, Liang Yang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zihan Yuan *Department of Gastroenterological Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Wei He *The First Clinical Medical College of Nanchang University, Nanchang, 330006, China.
Wenjia Luo *The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Chunxia HuangThe First Clinical Medical College of Nanchang University, Nanchang, 330006, China.
Miao LiQueen Mary College of Nanchang University, Nanchang, 330006, China.
Jie YouDepartment of Hepatic Surgery and Liver Transplantation Center, Guangdong Key Laboratory of Liver Disease Research, Guangdong Engineering Laboratory for Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, Guangdong, 510275, China.
Jiaqiang WuDepartment of Gastroenterological Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Kangping YangDepartment of Gastroenterological Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China. yangkangping0913@163.com.ORCID http://orcid.org/0000-0003-1298-0846
Liang YangDepartment of Gastroenterological Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China. ncu_yangliang@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal cancer, which is highly prevalent globally, constitutes a major threat to human health and life. The discovery of PD-L1/PD-1 has revolutionized immunotherapy, which has led to a shift in attention toward the antitumor functions of CD8 + T cells. CD8 + T cells are crucial effector cells in antitumor immunity, yet their functionality undergoes profound changes within the tumor microenvironment (TME). In the TME, gene mutations in cancer cells serve as initiating factors, remodeling the functions of various cells and the composition of noncellular substances. Cancer cells induce functional changes in other cells within the TME to favor their survival, notably impacting crucial antitumor effector cells such as CD8 + T cells, thereby furthering tumor progression. However, how tumor cells remodel CD8 + T cells remains inadequately understood, and targeted therapies against immune checkpoints face increasing challenges. An increasing number of findings suggest that miRNAs play a critical role in the process of remodeling CD8 + T cell function in tumors. Tumor cells regulate the expression of their own miRNAs to control the expression of surface molecules, modulate the release of secreted factors, or, through miRNA-containing exosomes, communicate with and remodel the function of CD8 + T cells. Elucidating the communication between CD8 + T cells and gastrointestinal cancer cells from a miRNA perspective to explain the shift of CD8 + T cells toward favorable types of tumors may inspire new therapeutic strategies. KEY MESSAGES: MicroRNAs regulate CD8+ T cells function in gastrointestinal cancers. MicroRNAs involve in crosstalk of gastrointestinal cancers with CD8+ T cells. MicroRNAs involve in crosstalk of the gastrointestinal immune microenvironment with CD8+ T cells. Focus on the application of targeted microRNA drugs and microRNA delivery strategies in gastrointestinal cancers.

Indexed as

CD8-Positive T-LymphocytesGastrointestinal NeoplasmsMicroRNAsAnimalsGene Expression Regulation, NeoplasticHumansImmunotherapyTumor MicroenvironmentMicroRNAsCD8 + T cellDelivery systemGastrointestinal cancerMicroRNAPD-L1TME

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.